➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Merck
AstraZeneca
Mallinckrodt
Colorcon
Baxter

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 6,790,618

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,790,618
Title: Method for determining the susceptibility of a NIDDM patent toward sulfonylurea therapy
Abstract:A method is provided for determining the susceptibility of a NIDDM patient towards sulfonylurea therapy by obtaining a sample from a NIDDM patient where the sample includes nucleic acid molecules containing a fragment of the SUR1 gene comprising the nucleotide in position -3 of exon 16 and detecting the presence or absence of the -3 t allele in position -3 of exon 6 whereby the presence of at least one -3 t allele identifies a NIDDM patient with a high susceptibility towards sulfonylurea therapy.
Inventor(s): Amouyel; Philippe (Marco-En-Baroeul, FR), Helbecque; Nicole (Marco-En-Baroeul, FR), Meirhaeghe; Aline (Lille, FR)
Assignee: Institut Pasteur de Lille (Lille, FR) Institut National de la Sante et de la Recherche Medicale (Inserm) (Paris, FR)
Application Number:09/913,731
Patent Claims:see list of patent claims

Details for Patent 6,790,618

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Institut Pasteur de Lille (Lille, FR) Institut National de la Sante et de la Recherche Medicale (Inserm) (Paris, FR) 2019-02-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Institut Pasteur de Lille (Lille, FR) Institut National de la Sante et de la Recherche Medicale (Inserm) (Paris, FR) 2019-02-19 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Institut Pasteur de Lille (Lille, FR) Institut National de la Sante et de la Recherche Medicale (Inserm) (Paris, FR) 2019-02-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
AstraZeneca
Merck
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.